ALNY
Alnylam Pharmaceuticals
$227.66
+$3.63 (+1.62%)Oct 26, 2026
Key metrics
The numbers that frame ALNY today
- Market cap
- $30.46B
- P/E (TTM)
- 38.3
- EV / FCF
- 40.0
- Gross margin
- 79.7%
- EV / Sales
- 6.6
- ROIC
- 22.3%
- Div yield
- 0%
- Debt / equity
- 2.2
- 52wk Low
- $197.81
- 52wk High
- $485.36
Growth
Revenue and earnings trend for ALNY
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about ALNY
Is Alnylam Pharmaceuticals a good buy?
Yes. Alnylam Pharmaceuticals has excellent quality, and it outweighs the poor momentum here. Growth looks excellent, which supports the long-term business case. We think Alnylam Pharmaceuticals is selling at a fair price.
What is the market capitalization of ALNY?
Alnylam Pharmaceuticals's market capitalization is $30.46B.
What is the P/E (TTM) ratio for ALNY stock?
Alnylam Pharmaceuticals's P/E (TTM) ratio is 38.3, based on trailing earnings.
What is the 52-week high for ALNY stock?
The 52-week high for Alnylam Pharmaceuticals is $485.36. The current close of $227.66 is 53.1% below that high.
What is the 52-week low for ALNY stock?
The 52-week low for Alnylam Pharmaceuticals is $197.81. The current close of $227.66 is 15.1% above that low.
Does ALNY stock pay dividends?
Alnylam Pharmaceuticals does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for ALNY?
Alnylam Pharmaceuticals's Debt / Equity ratio is 2.21.